NCT02869295View on ClinicalTrials.gov

A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

NKTR-214

Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.

Trial Locations (3)

77030

Investigator Site - Houston, Houston

97213

Investigator Site - Portland, Portland

06473

Investigator Site - New Haven, New Haven

Sponsors
All Listed Sponsors
lead

Nektar Therapeutics

INDUSTRY

NCT02869295 - A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter